JPMorgan analyst Robbie Marcus lowered the firm’s price target on Medtronic (MDT) to $100 from $105 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic resumed with an Outperform at Mizuho
- Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating
- AtriCure price target lowered to $53 from $64 at Canaccord
- Medtronic price target raised to $118 from $116 at Barclays
- Medtronic: Sustained Outperformance and Multi‑Year Growth Runway Driven by Cardiovascular and Robotics Pipelines